Skip to main content

Dermatology and Therapy OnlineFirst articles

Open Access 21.03.2024 | Brief Report

Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries

Alopecia areata (AA) is an autoimmune condition characterized by non-scarring hair loss, which can vary from small, well-defined patches to extensive, or even total, hair loss on the scalp, face, and/or body [ 1 ]. The lifetime incidence of AA is …

verfasst von:
Sergio Vañó-Galván, Alexander Egeberg, Bianca Maria Piraccini, Simran Marwaha, Catherine Reed, Erin Johansson, Frederick Durand, Anthony Bewley

Open Access 21.03.2024 | Original Research

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases worldwide [ 1 ]. AD usually presents with eczematous patches and intense itch that can significantly impair patients’ quality of life and productivity [ 1 ]. For decades …

verfasst von:
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna G. Burroni, Andrea Chiricozzi, Paolo Dapavo, Silvia M. Ferrucci, Massimo Gola, Maddalena Napolitano, Michela Ortoncelli, Maria T. Rossi, Claudio Sciarrone, Antonio Costanzo, Alessandra Narcisi

Open Access 14.03.2024 | Original Research

Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive Treatment

verfasst von:
Chun-Xia He, Chao Wu, Li Zhang, Hong-Zhong Jin

Open Access 12.03.2024 | Case Report

Atypical Fibroxanthoma Treated with a Topical Combination of Imiquimod, Tazarotene, and 5-Fluorouracil

This case report describes an 80-year-old man who presented with a growing erythematous nodule with erosion, measuring 0.6 cm × 0.6 cm, on his right temple. This lesion was later diagnosed as atypical fibroxanthoma (AFX). Instead of undergoing …

verfasst von:
William J. Nahm, Evangelos V. Badiavas, Robert S. Kirsner, Carter J. Boyd, Anita A. Arthur, Sean Bae, John Shen

Open Access 08.03.2024 | Original Research

Burden of Topical Treatments in Psoriasis and Preferred Criteria of Choice: A Survey-Based Evaluation of Patients in Europe

Psoriasis is a chronic inflammatory skin disease that is estimated to affect up to 125 million people worldwide, up to one-third of whom will develop psoriatic arthritis [ 1 – 3 ]. The condition affects both males and females, although presentation …

verfasst von:
Anthony Bewley, Lauren Hiribarne, Jordi Galván, Sicily Mburu

Open Access 19.12.2023 | Original Research

Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)

The development of biologic therapies has transformed the treatment of moderate-to-severe psoriasis (PsO) [ 1 , 2 ]. Yet, the chronic nature of psoriasis necessitates more studies showing the comparative effectiveness of biologics over longer …

verfasst von:
A. Pinter, A. Costanzo, S. Khattri, S. D. Smith, J. M. Carrascosa, Y. Tada, E. Riedl, A. Reich, A. Brnabic, N. Haustrup, A. Lampropoulou, I. Lipkovich, Z. Kadziola, C. Paul, C. Schuster